These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

398 related items for PubMed ID: 15642944

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse.
    Chopra V, Fox JH, Lieberman G, Dorsey K, Matson W, Waldmeier P, Housman DE, Kazantsev A, Young AB, Hersch S.
    Proc Natl Acad Sci U S A; 2007 Oct 16; 104(42):16685-9. PubMed ID: 17925440
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. AQAMAN, a bisamidine-based inhibitor of toxic protein inclusions in neurons, ameliorates cytotoxicity in polyglutamine disease models.
    Hong H, Koon AC, Chen ZS, Wei Y, An Y, Li W, Lau MHY, Lau KF, Ngo JCK, Wong CH, Au-Yeung HY, Zimmerman SC, Chan HYE.
    J Biol Chem; 2019 Feb 22; 294(8):2757-2770. PubMed ID: 30593503
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. An independent study of the preclinical efficacy of C2-8 in the R6/2 transgenic mouse model of Huntington's disease.
    Wang N, Lu XH, Sandoval SV, Yang XW.
    J Huntingtons Dis; 2013 Feb 22; 2(4):443-51. PubMed ID: 25062731
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Human cytomegalovirus UL97 kinase prevents the deposition of mutant protein aggregates in cellular models of Huntington's disease and ataxia.
    Tower C, Fu L, Gill R, Prichard M, Lesort M, Sztul E.
    Neurobiol Dis; 2011 Jan 22; 41(1):11-22. PubMed ID: 20732421
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Suppression of polyglutamine-induced toxicity in cell and animal models of Huntington's disease by ubiquilin.
    Wang H, Lim PJ, Yin C, Rieckher M, Vogel BE, Monteiro MJ.
    Hum Mol Genet; 2006 Mar 15; 15(6):1025-41. PubMed ID: 16461334
    [Abstract] [Full Text] [Related]

  • 15. Huntingtin aggregation and toxicity in Huntington's disease.
    Bates G.
    Lancet; 2003 May 10; 361(9369):1642-4. PubMed ID: 12747895
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Mutational analysis implicates the amyloid fibril as the toxic entity in Huntington's disease.
    Drombosky KW, Rode S, Kodali R, Jacob TC, Palladino MJ, Wetzel R.
    Neurobiol Dis; 2018 Dec 10; 120():126-138. PubMed ID: 30171891
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.